SLDBHealthcare · BiotechnologyThe 13 Wall Street analysts covering Solid Biosciences, Inc. hold a median 12-month price target of $18 — +163.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 44 of 100 as at 8 Oct 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores Solid Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (83): The shares have been drifting up relative to others.
Volatility (27): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on SLDB, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +163.9% from it.
Of the 20 most recent actions, 3 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 16 Sept 2026 | RBC Capital | Initiates | Outperform | $18 |
| 14 Sept 2026 | HC Wainwright & Co. | Reiterates | Buy | $25 |
| 27 Aug 2026 | Cantor Fitzgerald | Maintains | Overweight | — |
| 27 Aug 2026 | Cantor Fitzgerald | Maintains | Overweight | $16 → $26 |
| 21 Aug 2026 | Truist Securities | Maintains | Buy | — |
| 21 Aug 2026 | Truist Securities | Maintains | Buy | $16 → $20 |
| 3 June 2026 | HC Wainwright & Co. | Maintains | Buy | $20 → $25 |
| 3 June 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 18 May 2026 | Wedbush | Reiterates | Outperform | — |
| 13 May 2026 | Piper Sandler | Maintains | Overweight | — |
| 13 May 2026 | Wedbush | Maintains | Outperform | — |
| 25 Mar 2026 | JP Morgan | Maintains | Overweight | — |
| 23 Mar 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 20 Mar 2026 | Chardan Capital | Maintains | Buy | — |
| 20 Mar 2026 | Guggenheim | Initiates | Buy | — |
| 20 Mar 2026 | Needham | Reiterates | Buy | — |
| 12 Mar 2026 | Chardan Capital | Maintains | Buy | — |
| 12 Mar 2026 | Wedbush | Maintains | Outperform | — |
| 11 Mar 2026 | Wedbush | Reiterates | Outperform | — |
| 9 Feb 2026 | Needham | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SLDB appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 8 Oct 2026, Solid Biosciences, Inc. returned +8.1% against +16.2% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 73% of US stocks
Cheaper than 45% of US stocks
Cheaper than 72% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 18% of US stocks
Higher than 12% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Solid Biosciences, Inc. has a market value of $734.5M and an enterprise value of $384.5M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$207.1M.
Free cash flow in the twelve months to 30 June 2026: −$187.8M.
Solid Biosciences, Inc. spent $13.6M on share buybacks in the twelve months to 30 June 2026.
Trailing P/E: 0.2×; forward P/E: −4.0× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Solid Biosciences, Inc. employs 121 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Solid Biosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Solid Biosciences announced the grant of 8,150 restricted stock units to one newly hired employee as an inducement award under Nasdaq Listing Rule 5635(c)(4).
Why it matters — Investors tracking SLDB would note this as a routine equity-based hiring incentive, providing insight into recent personnel additions without indicating company performance.
The article covers Solid Biosciences' SGT-003 gene therapy for Duchenne muscular dystrophy, highlighting its funded cash runway into mid-2028 and a strategy of building both biological and controlled functional evidence rather than relying solely on microdystrophin expression. It also discusses the company's competitive positioning against Sarepta and Regenxbio, which depends on achieving clinically meaningful differentiation in function, safety, and eligibility under time pressure from advancing rivals.
Why it matters — A SLDB watcher would care because the article frames the company's differentiated SGT-003 approach and funding runway as central to its ability to compete in the Duchenne gene therapy space against advancing rivals.
Solid Biosciences Inc. (SLDB) presented at Citigroup's Biopharma Back to School Summit 2026, with a transcript of the presentation published by Seeking Alpha. The item covers the company's remarks at the investor conference.
Why it matters — A SLDB watcher would care because the presentation offers insight into the company's positioning and updates shared with investors at a major biopharma conference.
Solid Biosciences announced that its President and CEO, Bo Cumbo, and Gabriel Books, M.D., will participate in the 2026 Cantor Global Healthcare Conference. The company develops precision genetic medicines for neuromuscular and cardiac diseases.
Why it matters — The announcement signals upcoming investor-facing presentations that may provide updates on the company's pipeline and strategy.
The 13 Wall Street analysts covering Solid Biosciences, Inc. have a median 12-month price target of $18, with estimates ranging from $11 to $26. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 13 analysts covering Solid Biosciences, Inc., 13 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Solid Biosciences, Inc. 44 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 8 Oct 2026, Solid Biosciences, Inc. ranks 44 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (83 of 100).
No one can know that. What the data says: the median 12-month target from 13 analysts implies +163.9% from the last close, and Ticker Nerd's factor model ranks Solid Biosciences, Inc. 44 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Solid Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SLDB are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $11 to $26 over the next 12 months.
Solid Biosciences, Inc. returned +8.1% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Solid Biosciences Inc. is a precision genetic medicine company focused on developing gene therapy candidates for rare neuromuscular and cardiac diseases.
The most recent item we track (GlobeNewsWire, 1 Oct 2026): "Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)". Solid Biosciences announced the grant of 8,150 restricted stock units to one newly hired employee as an inducement award under Nasdaq Listing Rule 5635(c)(4).
Solid Biosciences Inc. is a precision genetic medicine company focused on developing gene therapy candidates for rare neuromuscular and cardiac diseases. Solid Biosciences Inc. advances a pipeline that includes programs for Duchenne muscular dystrophy, Friedreich’s ataxia, catecholaminergic polymorphic ventricular tachycardia, and certain forms of dilated cardiomyopathy. Its work centers on addressing severe genetic disorders through targeted therapies designed to act on the underlying disease biology rather than on symptoms alone. The company serves the biotechnology and rare-disease markets, where its research and clinical development efforts are aimed at conditions with significant unmet medical need. Headquartered in Charlestown, Massachusetts, Solid Biosciences Inc. operates as a life sciences company with a focus on translating genetic science into treatments for patients with serious inherited diseases.
CEO Mr. Alexander G. Cumbo · 121 employees · United States · https://www.solidbio.com
